A5078585608- Lipoproteins and Cardiovascular Health
- Cancer, Lipids, and Metabolism
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hormonal Regulation and Hypertension
- Lipid metabolism and disorders
- Peroxisome Proliferator-Activated Receptors
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Atherosclerosis and Cardiovascular Diseases
- Blood Pressure and Hypertension Studies
- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Cholesterol and Lipid Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease Diagnosis and Treatment
- Eicosanoids and Hypertension Pharmacology
- Cardiovascular Disease and Adiposity
- Pharmaceutical Economics and Policy
- Hemoglobinopathies and Related Disorders
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Systemic Lupus Erythematosus Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Potassium and Related Disorders
- Genetic factors in colorectal cancer
University of Ioannina
2016-2025
European Atherosclerosis Society
2021
University Hospital of Ioannina
2010-2017
Creative Research Enterprises (United States)
2016
University of Thessaly
2004-2005
Medical University of Sofia
2004
Thyroid dysfunction has a great impact on lipids as well number of other cardiovascular risk factors. Hypothyroidism is relatively common and associated with an unfavorable effect lipids. Substitution therapy beneficial for patients overt hypothyroidism, improving lipid profile. However, whether subclinical hypothyroidism should be treated or not matter debate. On the hand, hyperthyroidism can acquired hypocholesterolemia unexplained improvement Overall, thyroid taken into account when...
Abstract Patients with metabolic syndrome (MetS) usually have low high density lipoprotein cholesterol (HDL‐C) levels. We determined the HDL distribution profile as well HDL‐related associated phospholipase A 2 (HDL‐LpPLA ) and paraoxonase‐1 (PON1) activities in subjects MetS ( n = 189) but otherwise healthy. Age sex‐matched individuals 166) without served controls. The lower HDL‐C concentration patients was due to a reduction both large small subclasses P < 0.001 0.05, respectively). As...
The increase in physician-reported diabetes following rosuvastatin treatment the Justification for Use of Statins Prevention: an Intervention Trial Evaluating Rosuvastatin study has raised concerns whether this statin exerts a detrimental effect on glucose metabolism. We assessed across dose range homeostasis hyperlipidaemic patients with impaired fasting (IFG), who are at high risk to develop mellitus.The medical records 72 hypelipidaemic IFG 10 (RSV10 group), 20 (RSV20 group) and 40 mg/day...
Background: Familial hypercholesterolemia (FH) carries a high risk of atherosclerotic cardiovascular disease (ASCVD). As the population ages, age-related influence on clinical characteristics and outcomes becomes increasingly pertinent. This cross-sectional analysis from HELLAS-FH registry aims to explore potential differences in characteristics, treatment, ASCVD, goal achievement between those younger older than 65 years with FH. Results: A total 2273 adults heterozygous FH (51.4% males)...
Aims Three physical signs, namely tendon xanthomas, corneal arcus and xanthelasma, have been associated with heterozygous familial hypercholesterolemia (heFH). The prevalence clinical significance of these signs are not well established among contemporary heFH individuals. This study explored the frequency as association prevalent atherosclerotic cardiovascular disease (ASCVD) in Methods Data from Hellenic Familial Hypercholesterolemia Registry were applied for this analysis. diagnosis was...
Hepatitis E virus (HEV) is the causative agent for enteric non-A, non-B hepatitis. Transmission mainly via fecal-oral route but possibility of an additional parenteric transmission has been raised. Patients undergoing chronic hemodialysis (HD) have increased risk exposure to blood transmitted agents. Previous studies concerning prevalence antibodies HEV (anti-HEV) among HD patients gave conflicting results. The aim study presented here was determine anti-HEV a well-defined semi-rural region...
Objective:To compare the effects of simvastatin alone versus plus ezetimibe on small dense low-density lipoprotein cholesterol (sdLDL-C) concentration in subjects with primary hypercholesterolemia.Research design and methods:Patients LDL-C levels above those recommended by National Cholesterol Education Program Adult Treatment Panel III were randomized to open-label 40 mg (n = 50) or simvastatin/ezetimibe 10/10 as a fixed combination daily. LDL particle size (estimated electrophoresis),...
Abstract Lipoprotein (a) [Lp(a)] is an independent risk factor for cardiovascular disease. There are currently limited therapeutic options to lower Lp(a) levels. l ‐Carnitine has been reported reduce The aim of this study was compare the effect ‐carnitine/simvastatin co‐administration with that simvastatin monotherapy on levels in subjects mixed hyperlipidemia and elevated concentration. Subjects low‐density lipoprotein cholesterol (LDL‐C) >160 mg/dL, triacylglycerol (TAG) >150 mg/dL...